Lawrence P. Cogswell III

Lawrence P. Cogswell III, Ph.D., is a Principal at Hamilton, Brook, Smith & Reynolds, where he is also a member of the firm's Management Committee. His practice focuses heavily on intellectual property litigation, including patent, copyright, trademark, and trade secret cases, with significant experience in complex, high-stakes patent disputes. Dr. Cogswell is recognized for his integrated understanding of legal and technical aspects, drawing on a diverse scientific background.

Dr. Cogswell's expertise spans a broad range of technology areas, including pharmaceuticals (particularly Hatch-Waxman litigation), small molecule chemistry, biologics, biotechnology, software, antibodies, electronics and telecommunications, integrated circuits, medical devices, and mechanical devices. He represents clients in both offensive and defensive litigations, frequently defending operating companies against patent infringement actions, including those brought by non-practicing entities. For example, he has defended major communications companies and an internet services company against NPE lawsuits, often achieving favorable settlements. His tracked case, Unified Patents LLC v. Massachusetts Institute of Technology, further illustrates his role defending significant institutions in technology-focused disputes.

Beyond district court litigation, Dr. Cogswell frequently appears before the Patent Trial and Appeal Board (PTAB) for Inter Partes Review (IPR), Post-Grant Review (PGR), and Covered Business Method (CBM) proceedings. He has represented medical device manufacturers and telecommunications companies in such proceedings. Additionally, he handles appeals to the United States Court of Appeals for the Federal Circuit across various technologies, having also served as a judicial clerk for that court.

Dr. Cogswell earned his Ph.D. in biophysics and degrees in chemistry from Harvard University, and his J.D. from Yale Law School. He is also a seasoned patent prosecutor, managing portfolios and defending patents for universities and corporate clients, with a particular interest in the intersection of chemical, pharmaceutical, biologic, healthcare, medical device, diagnostic, and software sectors, including digital health.